NASDAQ
ZYBT
Last Price
US $0.71
Valuation
Financial
Performance
Financial risk - Cash flow debt coverage.
Zhengye Biotechnology Holding Limited cash flow to debt ratio of 17.76% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.
Financial risk - Healthy cash flow growth.
Zhengye Biotechnology Holding Limited's free cash flow has decreased -94.70% from $13.27M last year to $703.00K, signaling decreasing performance
Financial stability - Healthy debt to equity ratio.
Zhengye Biotechnology Holding Limited's debt to equity ratio is 0.30, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.
Financial stability - Healthy debt to equity ratio development.
Zhengye Biotechnology Holding Limited's debt has decreased relative to shareholder equity from 0.30 last year to 0.30 today, signaling strengthened financials
Financial risk - Net debt/EBITDA.
Zhengye Biotechnology Holding Limited has negative EBITDA, making leverage ratio unreliable
Financial risk - ICR.
Zhengye Biotechnology Holding Limited's interest coverage ratio is -38.13, which means that the company struggles to meet interest obligations, signaling financial risk.
Financial risk - Profit margin growth.
Zhengye Biotechnology Holding Limited's profit margin has decreased (-1.57K%) in the last year from 6.07% to -89.05%, signaling decreasing performance
Financial stability - Short term assets vs short term liabilities.
Zhengye Biotechnology Holding Limited's short-term assets of $137.42M exceed its short-term liabilities of $120.48M
Decreasing performance - ROA.
Zhengye Biotechnology Holding Limited's return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization
Decreasing performance - Absolute return on equity.
Zhengye Biotechnology Holding Limited's return on equity of -26.78%, is lower than 15.00%, indicating bad performance
Decreasing performance - Earnings quality.
Zhengye Biotechnology Holding Limited's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation
Increasing performance - Earnings stability.
Zhengye Biotechnology Holding Limited had positive net income in 4.00 out of 5 years, indicating stable and consistent earnings
Increasing performance - Free cash flow.
Zhengye Biotechnology Holding Limited has positive free cash flow, indicating the company generates cash after capital expenditures
Increasing performance - FCF yield.
Zhengye Biotechnology Holding Limited has a free cash flow yield of 2.09%, which is above the 2.00% threshold, indicating strong cash generation relative to market value
Decreasing performance - Healthy earnings growth.
Zhengye Biotechnology Holding Limited's yearly earnings has decreased -716.96% since last year from $11.31M to $-69.78M, signaling decreasing performance
Decreasing performance - Healthy revenue growth.
Zhengye Biotechnology Holding Limited's yearly revenue has decreased -37.56% since last year from $186.36M to $116.36M, signaling decreasing performance
Decreasing performance - ROIC.
ROIC -16.15% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.
Decreasing performance - 3-year revenue CAGR.
Zhengye Biotechnology Holding Limited's 3-year revenue CAGR of -23.53% is negative, indicating declining revenue over the past 3 years
Decreasing performance - Revenue consistency.
Zhengye Biotechnology Holding Limited had revenue growth in only 1.00 out of 5 years, indicating inconsistent revenue performance
Increasing performance - ROE consistency.
Zhengye Biotechnology Holding Limited had positive ROE in 4.00 out of 5 years, indicating consistent and reliable returns on equity
Overvalued - DCF valuation.
Zhengye Biotechnology Holding Limited has insufficient data to evaluate this check.
Overvalued - Earnings yield.
Zhengye Biotechnology Holding Limited has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Overvalued - EBITDA valuation.
Zhengye Biotechnology Holding Limited is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model
Overvalued - EV/EBITDA.
Zhengye Biotechnology Holding Limited has negative or missing EBITDA, making EV/EBITDA ratio unreliable
Overvalued - PEG ratio value.
Zhengye Biotechnology Holding Limited has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Undervalued - P/B ratio.
Zhengye Biotechnology Holding Limited has a price-to-book ratio of 0.11x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value
Undervalued - P/S ratio.
Zhengye Biotechnology Holding Limited has a price-to-sales ratio of 0.42x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue
Profit margin
Current Ratio
Capital Returns
-26.78%
Return on equity
ROIC: -16.15%
Valuation History
-3.5X
Price to Earnings
EV/EBITDA: -6.6X
Cash flow
Profit margin
-
(FY vs FY)
Cash flow Y/Y
-
(FY vs FY)
Fair Value
Market $0.71
—
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.